Cencora, Inc. $COR Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 12.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 432,701 shares of the company’s stock after selling 61,988 shares during the period. California Public Employees Retirement System’s holdings in Cencora were worth $135,929,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. JFS Wealth Advisors LLC lifted its stake in Cencora by 30.2% in the 4th quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock valued at $42,000 after buying an additional 29 shares in the last quarter. Apollon Wealth Management LLC boosted its holdings in Cencora by 0.5% in the 4th quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock worth $2,205,000 after buying an additional 30 shares during the last quarter. Accent Capital Management LLC increased its stake in Cencora by 36.1% during the 4th quarter. Accent Capital Management LLC now owns 113 shares of the company’s stock worth $38,000 after buying an additional 30 shares in the last quarter. MCF Advisors LLC increased its stake in Cencora by 11.0% during the 4th quarter. MCF Advisors LLC now owns 303 shares of the company’s stock worth $102,000 after buying an additional 30 shares in the last quarter. Finally, CYBER HORNET ETFs LLC raised its holdings in shares of Cencora by 6.8% during the fourth quarter. CYBER HORNET ETFs LLC now owns 485 shares of the company’s stock valued at $164,000 after acquiring an additional 31 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on COR shares. Bank of America raised their target price on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a research report on Wednesday, June 24th. Robert W. Baird reduced their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. William Blair began coverage on Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating on the stock. Citigroup decreased their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Weiss Ratings cut shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 30th. Eleven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $367.75.

Cencora Stock Performance

Shares of Cencora stock opened at $307.72 on Friday. The business’s 50 day moving average price is $279.98 and its 200 day moving average price is $317.68. The company has a market cap of $59.87 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 1.71 and a beta of 0.58. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the previous year, the company earned $4.42 earnings per share. The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, research analysts predict that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s dividend payout ratio is currently 18.40%.

Cencora announced that its board has authorized a stock repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other news, Director Lauren M. Tyler acquired 550 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.38% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.